MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
$44,661K
Accounts payable,
accrued expenses, due to...
$3,254K
Operating lease
liabilities
$214K
Inventory
-$2K
Net cash used in
operating activities
$31,596K
Canceled cashflow
$16,535K
Net increase
(decrease) in cash, cash...
-$19,043K
Canceled cashflow
$31,596K
Offering costs for common
stock and warrants...
-$1,334K
Payment of employee tax
obligations related to...
-$17K
Change in fair value of
derivative liabilities
$6,838K
Payable-in-kind interest on
credit agreement
-$5,434K
Stock-based compensation
expense
-$1,882K
Prepaid expenses and
other current assets
$1,232K
Accretion of debt discount
and amortization of...
-$681K
Operating lease
right-of-use assets
-$186K
Depreciation
-$168K
Accounts receivable
$114K
Net cash provided by
financing activities
-$50,639K
Canceled cashflow
$1,351K
Proceeds from issuance of
common stock and...
-$43,882K
Payment of principal of
long-term debt
$8,108K
Back
Back
Cash Flow
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)
source: myfinsight.com